SPARK: Safety Study of Pradaxa in Atrial Fibrillation Patients by Regulatory Requirement of Korea
- First Posted Date
- 2013-01-24
- Last Posted Date
- 2019-03-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 3182
- Registration Number
- NCT01774370
Pharmacokinetics, Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 2 Years of Age
- First Posted Date
- 2013-01-23
- Last Posted Date
- 2015-10-26
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT01773174
- Locations
- ๐บ๐ธ
1160.145.00007 Boehringer Ingelheim Investigational Site, Newark, New Jersey, United States
๐บ๐ธ1160.145.00010 Boehringer Ingelheim Investigational Site, Sacramento, California, United States
๐บ๐ธ1160.145.00009 Boehringer Ingelheim Investigational Site, Louisville, Kentucky, United States
Investigation of Potential Drug-drug Interaction of Volasertib With Itraconazole in Patients With Various Tumours
- First Posted Date
- 2013-01-21
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 28
- Registration Number
- NCT01772563
- Locations
- ๐ญ๐บ
National Institute of Oncology, Budapest, Hungary
๐ญ๐บPRA Hungary Ltd., Phase I. Clinical Pharmacology Unit, Budapest, Hungary
Relative Bioavailability of a Single Dose of Nintedanib Given Alone and in Combination With Multiple Doses of Rifampicin
- First Posted Date
- 2013-01-17
- Last Posted Date
- 2014-11-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 26
- Registration Number
- NCT01770392
- Locations
- ๐ฉ๐ช
1199.162.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Relative Bioavailability of BI 201335 Capsule Versus Three Different Oral Solutions
- Conditions
- Healthy
- Interventions
- Drug: BI 201335 (Test)Drug: BI 201335 (Reference)
- First Posted Date
- 2013-01-10
- Last Posted Date
- 2015-07-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 56
- Registration Number
- NCT01764945
- Locations
- ๐ฉ๐ช
1220.46.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
To Investigate the Safety, Tolerability, Pharmacokinetics and the Relative Bioavailability of BI 1026706
- First Posted Date
- 2013-01-08
- Last Posted Date
- 2019-03-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 80
- Registration Number
- NCT01763333
- Locations
- ๐ฉ๐ช
1320.1.1 Boehringer Ingelheim Investigational Site, Ingelheim, Germany
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effects of Multiple Rising Subcutaneous Doses of BI 655064 in Healthy Volunteers and in Rheumatoid Arthritis Patients With Prior Inadequate Response to Methotrexate Therapy
- Conditions
- Arthritis, RheumatoidHealthy
- Interventions
- Drug: Placebo matching BI 655064
- First Posted Date
- 2012-12-18
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 107
- Registration Number
- NCT01751776
- Locations
- ๐จ๐ฟ
1293.2.00028 Boehringer Ingelheim Investigational Site, Zlin, Czechia
๐จ๐ฟ1293.2.00024 Boehringer Ingelheim Investigational Site, Uherske Hradiste, Czechia
๐จ๐ฟ1293.2.00049 Boehringer Ingelheim Investigational Site, Olomouc, Czechia
Safety, Tolerability and Pharmacokinetics of Different Multiple Doses of BI 207127 BID and Multiple Doses of BI 207127 Combined With Faldaprevir in Healthy Male and Female Subjects
- Conditions
- Healthy
- Interventions
- Drug: BI 207127 + faldaprevir
- First Posted Date
- 2012-11-30
- Last Posted Date
- 2016-04-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 32
- Registration Number
- NCT01737996
- Locations
- ๐ฉ๐ช
1241.35.1 Boehringer Ingelheim Investigational Site, Mannheim, Germany
Investigation of Drug-drug Interaction of Dabigatran and Ticagrelor
- First Posted Date
- 2012-11-28
- Last Posted Date
- 2014-05-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 48
- Registration Number
- NCT01734772
- Locations
- ๐ฉ๐ช
1160.142.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Relative Bioavailability Study to Investigate and to Compare Two Different Formulations of Hyoscine Butylbromide in Healthy Male and Female Volunteers
- First Posted Date
- 2012-11-28
- Last Posted Date
- 2019-04-23
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT01734902
- Locations
- ๐ฉ๐ช
202.846.1 Boehringer Ingelheim Investigational Site, Ingelheim, Germany